Targeting CRTC2 reverses mutant NSCLC tumor resistance to immunotherapy.
2/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: tumors harboring mutations are resistant to standard of care anti-PD-1/PD-L1 blockade
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Mechanistically, the abrogation of the binding between CRTC2 and CREB was sufficient to restore sensitivity to immunotherapy. These findings provide critical insights into the central role of CRTC2 in modulating response to ICB and identify the disruption of CRTC2-CREB interaction as a potential therapeutic approach for this patient population.
OpenAlex 토픽 ·
Lung Cancer Treatments and Mutations
Cancer Immunotherapy and Biomarkers
Melanoma and MAPK Pathways
Non-small cell lung cancer (NSCLC) patients with tumors harboring mutations are resistant to standard of care anti-PD-1/PD-L1 blockade.
APA
Dimitri Robay, Ole Ackermann, et al. (2026). Targeting CRTC2 reverses mutant NSCLC tumor resistance to immunotherapy.. Proceedings of the National Academy of Sciences of the United States of America, 123(17), e2508762123. https://doi.org/10.1073/pnas.2508762123
MLA
Dimitri Robay, et al.. "Targeting CRTC2 reverses mutant NSCLC tumor resistance to immunotherapy.." Proceedings of the National Academy of Sciences of the United States of America, vol. 123, no. 17, 2026, pp. e2508762123.
PMID
42018410 ↗
Abstract 한글 요약
Non-small cell lung cancer (NSCLC) patients with tumors harboring mutations are resistant to standard of care anti-PD-1/PD-L1 blockade. For this patient population there are no currently available tailored treatments, underlying the critical need to discover effective therapeutic strategies. In this study, we dissected the molecular mechanisms responsible for -mediated resistance to immune checkpoint blockade (ICB) and identified CRTC2, a coactivator of the transcription factor cAMP response element-binding protein (CREB), as a key signaling node regulating -dependent cell-extrinsic functions. CRTC2 deletion remodeled the immune profiles of -KO tumors and resensitized them to anti-PD-1 treatment, comparably to -proficient tumors. Mechanistically, the abrogation of the binding between CRTC2 and CREB was sufficient to restore sensitivity to immunotherapy. These findings provide critical insights into the central role of CRTC2 in modulating response to ICB and identify the disruption of CRTC2-CREB interaction as a potential therapeutic approach for this patient population.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Carcinoma
- Non-Small-Cell Lung
- Transcription Factors
- Lung Neoplasms
- Immunotherapy
- Drug Resistance
- Neoplasm
- Animals
- Mice
- Mutation
- Protein Serine-Threonine Kinases
- AMP-Activated Protein Kinase Kinases
- Cell Line
- Tumor
- Immune Checkpoint Inhibitors
- Cyclic AMP Response Element-Binding Protein
- Knockout
- Signal Transduction
- CRTC2
- ICB resistance
- LKB1
- STK11
- lung cancer
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.